➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Harvard Business School
Colorcon
Baxter
McKesson

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CALQUENCE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Calquence

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03516617 ↗ Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting National Cancer Institute (NCI) Phase 2 2018-09-10 This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
NCT03516617 ↗ Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting Mayo Clinic Phase 2 2018-09-10 This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
NCT03580928 ↗ Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL Recruiting Acerta Pharma Phase 2 2018-07-30 This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL). The drugs involved in this study are: - Acalabrutinib - Venetoclax - Obinutuzmab
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Calquence

Condition Name

Condition Name for Calquence
Intervention Trials
Mantle Cell Lymphoma 9
Chronic Lymphocytic Leukemia 5
Refractory Chronic Lymphocytic Leukemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Calquence
Intervention Trials
Lymphoma 23
Lymphoma, Mantle-Cell 12
Leukemia, Lymphocytic, Chronic, B-Cell 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Calquence

Trials by Country

Trials by Country for Calquence
Location Trials
United States 36
Italy 1
Austria 1
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Calquence
Location Trials
Texas 7
Massachusetts 4
Washington 4
California 3
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Calquence

Clinical Trial Phase

Clinical Trial Phase for Calquence
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Calquence
Clinical Trial Phase Trials
Not yet recruiting 32
Recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Calquence

Sponsor Name

Sponsor Name for Calquence
Sponsor Trials
AstraZeneca 14
National Cancer Institute (NCI) 14
M.D. Anderson Cancer Center 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Calquence
Sponsor Trials
Other 39
Industry 18
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Dow
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.